Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Breast Cancer
Interventions: DRUG: BKM120 and Olaparib|DRUG: BYL719 and Olaparib
Sponsor: Dana-Farber Cancer Institute
Collaborators: Novartis|AstraZeneca